Related Experiment Video
Updated: May 27, 2026

Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
Published on: May 5, 2016
Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin
Marzia Rahman1, Shukho Kim, Sung Min Kim
1Department of Microbiology, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea.
Abstract:
Lytic bacteriophages (phages) have been investigated as treatments for bacterial infectious diseases. An induced phage, SAP-26, was isolated from a clinical isolate of Staphylococcus aureus. It belongs to the family Siphoviridae and its genome consists of double-stranded 41,207 bp DNA coding for 63 open reading frames. The phage SAP-26 showed a wide spectrum of lytic activity against both methicillin-resistant S. aureus and methicillin-susceptible S.aureus. Furthermore, combined treatment with a phage and antimicrobial agents showed a strong biofilm removal effect which induced structural changes in the biofilm matrix and a substantial decrease in the number of bacteria. Such a broad host range in S. aureus and biofilm removal activity of the phage SAP-26 suggests the possibility of its use as a therapeutic phage in combination with appropriate antimicrobial agent(s). Among the three antimicrobial agents combined with phage, the combination of rifampicin showed the best biofilm removal effect. To the authors' knowledge, this study showed for the first time that S. aureus biofilm could be efficiently eradicated with the mixture of phage and an antimicrobial agent, especially rifampicin.
Insights
Phage SAP-26 effectively targets Staphylococcus aureus biofilms. Combining this lytic bacteriophage with rifampicin offers a novel strategy for eradicating bacterial infections and biofilms.
Area of Science:
- Microbiology
- Bacteriophage Therapy
- Infectious Diseases
Background:
- Bacterial infectious diseases pose significant challenges, with Staphylococcus aureus being a common pathogen.
- Antimicrobial resistance necessitates the exploration of alternative therapeutic strategies.
- Bacteriophages (phages) are viruses that infect bacteria and have shown potential as antimicrobial agents.
Purpose of the Study:
- To isolate and characterize a novel lytic bacteriophage targeting Staphylococcus aureus.
- To evaluate the efficacy of phage SAP-26, alone and in combination with antimicrobial agents, against S. aureus biofilms.
- To investigate the potential of phage-antibiotic combinations for treating S. aureus infections.
Main Methods:
- Isolation and characterization of lytic bacteriophage SAP-26 from a clinical Staphylococcus aureus isolate.
- Genomic analysis of phage SAP-26 (41,207 bp double-stranded DNA, 63 open reading frames).
- Assessment of phage SAP-26's lytic activity against methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA).
- Evaluation of combined treatment effects of phage SAP-26 and antimicrobial agents on S. aureus biofilm removal.
Main Results:
- Phage SAP-26 demonstrated broad lytic activity against both MRSA and MSSA strains.
- Combined treatment with phage SAP-26 and antimicrobial agents significantly reduced S. aureus biofilms.
- The combination of phage SAP-26 and rifampicin exhibited the most potent biofilm removal effect, inducing structural changes and reducing bacterial numbers.
Conclusions:
- Phage SAP-26 is a promising therapeutic agent due to its broad host range against S. aureus.
- The combination of phage SAP-26 and rifampicin represents a novel and effective approach for eradicating S. aureus biofilms.
- This study highlights the potential of phage-antibiotic synergy in combating challenging bacterial infections.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Biofilms
Gene Regulation in Microbial Communities: Quorum Sensing

